• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    VBL Therapeutics Announces Appointment of Sam Backenroth as Chief Financial Officer and Establishes Operations in the United States

    10/5/21 8:00:00 AM ET
    $NBSE
    $VBLT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NBSE alert in real time by email

    TEL AVIV, Israel and NEW YORK, Oct. 05, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) today announced the appointment of Sam Backenroth as chief financial officer (CFO) effective immediately. Mr. Backenroth is an accomplished corporate finance veteran with demonstrated success in building and financing private and public biotechnology companies. In connection with the appointment, VBL established U.S. operations in New York, which will be managed by Mr. Backenroth, and he will be responsible for leading the company's future financing and business development activities to support the company's growth initiatives. Mr. Backenroth succeeds Mr. Amos Ron, who is retiring but will continue to serve as corporate secretary and in an advisory capacity.

    "On behalf of the entire board of directors and management team, I want to thank Amos Ron for his outstanding service to VBL, and his leadership over the past decade. We are grateful Amos will continue as corporate secretary and an advisor to the company," said Prof. Dror Harats, M.D., chief executive officer, VBL Therapeutics. "We are tremendously pleased to welcome Sam to the VBL executive leadership team and expand our operations in the United States. Sam has a proven track record in corporate finance, strategy, operations and business development. His leadership and strong investor and banking relationships will be invaluable as we as we enter a new era of innovation and growth for VBL as a leading global biotech company."

    Most recently, Mr. Backenroth was the chief financial officer at NeuBase Therapeutics (NASDAQ:NBSE), a novel genetic medicine platform company focused on rare genetic diseases and oncology. While at NeuBase, Mr. Backenroth helped build the finance and operations functions, took the company public, and raised approximately $100 million in equity capital.

    "I am excited to join VBL to advance the company's financial and business objectives and support its continued growth and development of its first-in-class pipeline of programs in oncology and immuno-inflammation. The company is at an exciting point, with the ongoing Phase 3 OVAL registration-enabling study of VB-111 in ovarian cancer advancing to the planned progression free survival readout in the second half of 2022 and the expected filing of an IND for the VB-601 MOSPD2 program in an immunology application in 2022," said Mr. Backenroth. "VBL's gene targeting precision medicine platform, coupled with its vision and expertise in biology, positions the company to make meaningful improvements to underserved patient populations and unlock significant shareholder value. I look forward to working with the team to capitalize on the tremendous potential for VBL to bring novel gene therapies to people living with cancer and immuno-inflammatory disorders."

    Prior to his tenure at NeuBase, Mr. Backenroth was the CFO of Ohr Pharmaceutical, where he was instrumental in the company's growth from startup to a public market capitalization of several hundred million and helped move its lead program from preclinical into late-stage clinical development. He is also a founder of Orphion Therapeutics, a company focused on one-time gene therapy treatments for ocular and central nervous system manifestations of ultra-rare diseases, and DepYmed, Inc., a pharmaceutical company focused on a novel phosphatase inhibition technology platform for rare diseases and cancer, where he currently serves as a member of the Board of Directors. Mr. Backenroth began his career as an investment banker with The Benchmark Company LLC, where he raised capital and provided advisory services for biotechnology companies. Mr. Backenroth earned a bachelor of science degree in finance from Touro College in New York.

    VBL has a burgeoning U.S. presence at both the board and executive level and its headquarters and manufacturing operations will continue to be located in Israel.

    About VBL Therapeutics

    Vascular Biogenics Ltd., operating as VBL Therapeutics (VBL), is a late clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer and immune or inflammatory indications. VBL has developed three platform technologies: VTS™, a gene-therapy based platform for targeting newly formed blood vessels with focus on cancer, an antibody-based platform targeting MOSPD2 for anti-inflammatory and immuno-oncology applications, and the lecinoxoids platform, comprised of a family of small-molecules for immune-related indications. VBL's lead oncology product candidate, ofranergene obadenovec (VB-111; ‘ofra-vec'), is an investigational, potentially first-in-class, targeted anti-cancer gene-therapy agent in development that is designed to treat a wide range of solid tumors. VB-111 is currently being studied in a Phase 3 registration-enabling trial (NCT03398655) for recurrent platinum-resistant ovarian cancer. To learn more about VBL Therapeutics, please visit vblrx.com or follow the company on LinkedIn, Twitter, YouTube or Facebook.

    Forward Looking Statements

    This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to," "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. These forward-looking statements may include, but are not limited to, statements regarding anticipated timing of PFS readout for the OVAL trial, VBL's business development efforts and financing plans as well as its ability to bring novel gene therapies to patients. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, the risk that historical clinical trial results may not be predictive of future trial results, that financial resources do not last for as long as anticipated, and that VBL may not realize the expected benefits of its intellectual property protection. In particular, the addition of PFS as a primary endpoint in the OVAL trial is not assurance that the trial will meet either of its primary endpoints, that it will do so within any particular time frame, or that VBL will obtain positive results to support any marketing application or further development of this candidate. A further list and description of these risks, uncertainties and other risks can be found in VBL's regulatory filings with the U.S. Securities and Exchange Commission, including in its annual report on Form 20-F for the year ended December 31, 2020, and subsequent filings with the SEC. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. VBL undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

    CONTACT:

    Catherine Day

    +1-917-763-2709

    [email protected]

    A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/cb71632d-1aeb-4acf-9fc1-9725a13e732f 



    Primary Logo

    Get the next $NBSE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NBSE
    $VBLT

    CompanyDatePrice TargetRatingAnalyst
    Vascular Biogenics Ltd.
    $VBLT
    7/20/2022Outperform → Perform
    Oppenheimer
    Vascular Biogenics Ltd.
    $VBLT
    7/20/2022Buy → Neutral
    H.C. Wainwright
    Vascular Biogenics Ltd.
    $VBLT
    7/18/2022$5.50Outperform
    Oppenheimer
    Vascular Biogenics Ltd.
    $VBLT
    4/28/2022$5.00Buy
    Chardan Capital Markets
    More analyst ratings

    $NBSE
    $VBLT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by NeuBase Therapeutics Inc. (Amendment)

      SC 13G/A - NeuBase Therapeutics, Inc. (0001173281) (Subject)

      2/14/24 4:46:42 PM ET
      $NBSE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Vascular Biogenics Ltd. (Amendment)

      SC 13G/A - Notable Labs, Ltd. (0001603207) (Subject)

      1/11/24 5:22:04 PM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Vascular Biogenics Ltd.

      SC 13D - Notable Labs, Ltd. (0001603207) (Subject)

      10/19/23 1:34:02 PM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NBSE
    $VBLT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Vascular Biogenics downgraded by Oppenheimer

      Oppenheimer downgraded Vascular Biogenics from Outperform to Perform

      7/20/22 9:01:50 AM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vascular Biogenics downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Vascular Biogenics from Buy to Neutral

      7/20/22 7:39:29 AM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer resumed coverage on Vascular Biogenics with a new price target

      Oppenheimer resumed coverage of Vascular Biogenics with a rating of Outperform and set a new price target of $5.50

      7/18/22 9:22:46 AM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NBSE
    $VBLT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NeuBase Therapeutics Announces Receipt of Notice from Nasdaq

      PITTSBURGH, April 05, 2024 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ:NBSE) ("NeuBase" or the "Company") today reported that it received a notice (the "Notice) on April 4, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it was not in compliance with Nasdaq's continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the "Rule") as a result of its failure to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the "Form 10-K") in a timely manner. This Notice has no immediate effect on the listing of the Company's common stock on the Nasdaq Capital Market. Under Nasdaq rule

      4/5/24 4:05:56 PM ET
      $NBSE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Psychemedics Corporation Appoints Daniella Mehalik as VP - Finance

      ACTON, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), a global leader in hair testing for substance abuse, proudly announces the appointment of Daniella Mehalik as its new Vice President - Finance. In her new role, Ms. Mehalik will assume responsibility for directing and managing all financial activities at Psychemedics, including comprehensive oversight of external reporting and internal analysis. Reporting directly to CEO and President Brian Hullinger, she will play a pivotal role in steering the financial trajectory of the organization. Bringing over a decade of extensive experience to her new position, Ms. Mehalik possesses a robust background in acco

      11/27/23 9:00:00 AM ET
      $NBSE
      $PMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical Specialities
    • Notable Labs Closes Merger Transaction With VBL Therapeutics

      - Notable expects to initiate trading on the Nasdaq Capital Market under ticker symbol "NTBL" effective at market open on October 17 - - Aggregate net transaction proceeds expected to fund planned operations into 2025 - - Completed previously announced $10.3 million private placement with leading healthtech-focused investors, led by Builders VC, B Capital Group, Y Combinator, First Round Capital, and Founders Fund - - Predictive Precision Medicines Platform ("PPMP") applied to select and develop two clinical-stage therapeutic candidates with lead programs in acute myeloid leukemia ("AML"); four Phase 2 milestones expected by 1Q 2025 including Phase 2a results for lead asset Volasertib in

      10/16/23 1:01:41 PM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NBSE
    $VBLT
    Leadership Updates

    Live Leadership Updates

    See more
    • Psychemedics Corporation Appoints Daniella Mehalik as VP - Finance

      ACTON, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), a global leader in hair testing for substance abuse, proudly announces the appointment of Daniella Mehalik as its new Vice President - Finance. In her new role, Ms. Mehalik will assume responsibility for directing and managing all financial activities at Psychemedics, including comprehensive oversight of external reporting and internal analysis. Reporting directly to CEO and President Brian Hullinger, she will play a pivotal role in steering the financial trajectory of the organization. Bringing over a decade of extensive experience to her new position, Ms. Mehalik possesses a robust background in acco

      11/27/23 9:00:00 AM ET
      $NBSE
      $PMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical Specialities
    • Alpha Tau Medical Ltd. Appoints Ruth Alon to its Board of Directors

      JERUSALEM, March 21, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. (NASDAQ:DRTS), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced the appointment of Ms. Ruth (Ruti) Alon to its Board of Directors, effective immediately. "We are pleased to welcome Ruti as the newest member of our Board of Directors," said Uzi Sofer, Chief Executive Officer and Chairman of Alpha Tau. "Ruti's extensive knowledge and experience advising healthcare companies through financial and strategic operations will be a tremendous asset to the Company. We are eager to have her on board and benefit from her insights into our corporate and clinical plan as we grow the Company." Ruti

      3/21/22 4:05:00 PM ET
      $DRTS
      $MACA
      $VBLT
      Medical/Dental Instruments
      Health Care
      Blank Checks
      Finance
    • NeuBase Therapeutics Reports Business Update and Financial Results for the First Quarter of Fiscal Year 2022

      Investigational New Drug (IND)-enabling studies for the myotonic dystrophy type 1 (DM1) program development candidate continue as planned; invited to present new rodent pharmacokinetic (PK) and bioavailability data in an oral presentation at an upcoming scientific meeting; expects to submit an IND application to the U.S. Food and Drug Administration (FDA) in the fourth quarter (Q4) of calendar year (CY) 2022Good Manufacturing Practice (GMP) manufacturing to support Phase 1/2 clinical trials for DM1 program successfully implemented Expects to nominate a development candidate and initiate scale-up and toxicology activities for a systemically administered, allele-selective candidate for the Hun

      2/10/22 7:00:00 PM ET
      $NBSE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NBSE
    $VBLT
    SEC Filings

    See more
    • NeuBase Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - NeuBase Therapeutics, Inc. (0001173281) (Filer)

      5/22/24 4:59:01 PM ET
      $NBSE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by NeuBase Therapeutics Inc.

      DEFA14A - NeuBase Therapeutics, Inc. (0001173281) (Filer)

      5/13/24 9:00:28 PM ET
      $NBSE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NeuBase Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - NeuBase Therapeutics, Inc. (0001173281) (Filer)

      5/13/24 4:25:31 PM ET
      $NBSE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NBSE
    $VBLT
    Financials

    Live finance-specific insights

    See more
    • Notable Labs Closes Merger Transaction With VBL Therapeutics

      - Notable expects to initiate trading on the Nasdaq Capital Market under ticker symbol "NTBL" effective at market open on October 17 - - Aggregate net transaction proceeds expected to fund planned operations into 2025 - - Completed previously announced $10.3 million private placement with leading healthtech-focused investors, led by Builders VC, B Capital Group, Y Combinator, First Round Capital, and Founders Fund - - Predictive Precision Medicines Platform ("PPMP") applied to select and develop two clinical-stage therapeutic candidates with lead programs in acute myeloid leukemia ("AML"); four Phase 2 milestones expected by 1Q 2025 including Phase 2a results for lead asset Volasertib in

      10/16/23 1:01:41 PM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NeuBase Therapeutics Issues Statement Regarding Filing By Shareholder

      PITTSBURGH, Sept. 08, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ:NBSE) ("NeuBase" or the "Company") today issued the following statement regarding the Schedule 13D filed with the U.S. Securities and Exchange Commission on August 31, 2023, by Symetryx Corporation ("Symetryx") and their subsequent press release issued on September 6, 2023. "The NeuBase Board of Directors ("Board") appreciates input from its shareholders. The Board remains committed to completing its comprehensive exploration of strategic alternatives focused on maximizing shareholder value. The Board does not believe that shareholder value will be enhanced by issuing the special $1 per share dividend Symetr

      9/8/23 7:00:00 AM ET
      $NBSE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SYMETRYX CORPORATION ACQUIRES 20% STOCK IN NEUBASE

      URGES BOARD TO CONSIDER A $1 DIVIDEND TORONTO, Sept. 6, 2023 /PRNewswire/ - Today, Symetryx Corporation ("Symetryx") announced that it has acquired 20% of the issued and outstanding common stock in Neubase Therapeutics Inc. (NASDAQ:NBSE) ("Neubase"). Symetryx is now urging the Board to issue a special $1 per share dividend. Symetryx has bought these shares on the open market and intends to engage with the management of Neubase to chart the best path forward for shareholders. Neubase, as disclosed in its previous news releases, is currently undergoing a strategic review of the company's operations. Symetryx notes that for the quarter ended June 30, 2023, Neubase reported approximate cash bala

      9/6/23 10:00:00 AM ET
      $NBSE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NBSE
    $VBLT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Feinberg Peter

      4 - Notable Labs, Ltd. (0001603207) (Issuer)

      1/26/24 11:05:45 AM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Patsi Tuomo

      4 - Notable Labs, Ltd. (0001603207) (Issuer)

      1/26/24 11:05:20 AM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Galen Michele

      4 - Notable Labs, Ltd. (0001603207) (Issuer)

      1/26/24 11:04:43 AM ET
      $VBLT
      Biotechnology: Pharmaceutical Preparations
      Health Care